NCT04590963 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 247
- group Id
- BG001
- value
- 123
- group Id
- BG002
- value
- 370
- units
- Participants
- groups
- description
- Participants received IV monalizumab 750 mg Q2W and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
- id
- BG000
- title
- Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2
- description
- Participants receieved IV placebo matched to monalizumab Q2W and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
- id
- BG001
- title
- Placebo Q2W + Cetuximab 400 mg/m^2
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.4
- value
- 62.0
- group Id
- BG001
- spread
- 9.6
- value
- 61.4
- group Id
- BG002
- spread
- 10.1
- value
- 61.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 71
- title
- Female
- measurements
- group Id
- BG000
- value
- 205
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 299
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 17
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 223
- group Id
- BG001
- value
- 114
- group Id
- BG002
- value
- 337
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 16
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 66
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 96
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 258
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 13
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Baseline analysis population included all participants randomized up to the safety DCO date of 01Sep2022.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 247
- group Id
- BG001
- value
- 123
- group Id
- BG002
- value
- 370
- units
- Participants
- groups
- description
- Participants received IV monalizumab 750 mg Q2W and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
- id
- BG000
- title
- Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2
- description
- Participants receieved IV placebo matched to monalizumab Q2W and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
- id
- BG001
- title
- Placebo Q2W + Cetuximab 400 mg/m^2
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.4
- value
- 62.0
- group Id
- BG001
- spread
- 9.6
- value
- 61.4
- group Id
- BG002
- spread
- 10.1
- value
- 61.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 71
- title
- Female
- measurements
- group Id
- BG000
- value
- 205
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 299
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 17
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 223
- group Id
- BG001
- value
- 114
- group Id
- BG002
- value
- 337
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 16
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 66
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 96
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 258
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 13
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Baseline analysis population included all participants randomized up to the safety DCO date of 01Sep2022.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle